Edwards Lifesciences Stock Forecast, Price & News

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 3 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences or view top-rated stocks.

22 Wall Street research analysts have issued 1-year target prices for Edwards Lifesciences' stock. Their EW stock forecasts range from $105.00 to $145.00. On average, they predict Edwards Lifesciences' share price to reach $128.71 in the next year. This suggests a possible upside of 44.6% from the stock's current price.
View analysts' price targets for Edwards Lifesciences or view top-rated stocks among Wall Street analysts.

Edwards Lifesciences' stock was trading at $129.55 on January 1st, 2022. Since then, EW shares have decreased by 31.3% and is now trading at $89.00.
View the best growth stocks for 2022 here.

Edwards Lifesciences saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 6,560,000 shares, an increase of 27.4% from the May 15th total of 5,150,000 shares. Based on an average daily trading volume, of 2,820,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 1.1% of the shares of the company are sold short.
View Edwards Lifesciences' Short Interest.

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Edwards Lifesciences.

Edwards Lifesciences Co. (NYSE:EW) issued its quarterly earnings results on Tuesday, April, 26th. The medical research company reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.02. The medical research company earned $1.34 billion during the quarter, compared to analyst estimates of $1.31 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 25.80% and a net margin of 28.72%. The company's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.54 EPS.
View Edwards Lifesciences' earnings history.

Shares of Edwards Lifesciences split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY22 earnings guidance on Tuesday, April, 26th. The company provided earnings per share (EPS) guidance of $2.50-2.65 for the period, compared to the consensus estimate of $2.56. The company issued revenue guidance of $5.5-6.0 billion, compared to the consensus revenue estimate of $5.76 billion.

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Insulet (PODD), Teleflex (TFX) and Abiomed (ABMD).
View all of EW's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.17%), Vanguard Group Inc. (8.00%), State Street Corp (4.33%), Capital International Investors (3.56%), Bank of New York Mellon Corp (3.51%) and Brown Advisory Inc. (2.67%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link.
View institutional ownership trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Capital Research Global Investors, Wellington Management Group LLP, Invesco Ltd., Sumitomo Mitsui Trust Holdings Inc., Neuberger Berman Group LLC, Canada Pension Plan Investment Board, and Aviva PLC. Company insiders that have sold Edwards Lifesciences company stock in the last two years include Bernard J Zovighian, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, and Scott B Ullem.
View insider buying and selling activity for Edwards Lifesciences or view top insider-selling stocks.

EW stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., CI Investments Inc., Stonehage Fleming Financial Services Holdings Ltd, Lord Abbett & CO. LLC, Bank of America Corp DE, Swiss National Bank, Bridgewater Associates LP, and Fisher Asset Management LLC.
View insider buying and selling activity for Edwards Lifesciences or or view top insider-buying stocks.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EW stock can currently be purchased for approximately $89.00.

Edwards Lifesciences (NYSE:EW) has a market capitalization of $55.34 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.439990 on an earnings per share basis.

Edwards Lifesciences employs 15,700 workers across the globe.

Edwards Lifesciences was founded in 1958.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for Edwards Lifesciences is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at [email protected], or via fax at 949-250-2525.